UnitedHealth Group stock (US91324P1021): Q1 earnings beat, JPMorgan raises price target

UnitedHealth Group reported first-quarter earnings of $7.23 per share, beating consensus estimates, while JPMorgan lifted its price target to $420 on April 28.

UnitedHealth Group reported stronger-than-expected first-quarter results on April 21, 2026, posting earnings per share of $7.23 versus the consensus estimate of $6.76, according to MarketBeat as of May 11, 2026. Revenue for the quarter reached $111.65 billion, surpassing the expected $109.84 billion. The healthcare conglomerate's outperformance has contributed to a year-to-date gain of 14.9%, with shares trading at $379.49 as of May 8, 2026.

Following the earnings announcement, JPMorgan raised its price target on UnitedHealth Group to $420 from $389 on April 28, 2026, while reiterating an Overweight rating, according to InsiderMonkey as of May 11, 2026. The analyst action reflects confidence in the company's operational execution and market position.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: UnitedHealth Group Incorporated
• Sector/industry: Healthcare, managed care, and health insurance
• Headquarters/country: United States
• Core markets: US health insurance, pharmacy benefits management, healthcare services
• Key revenue drivers: Managed care premiums, pharmacy benefits, healthcare services
• Home exchange/listing venue: NYSE (UNH)
• Trading currency: USD

UnitedHealth Group: core business model

UnitedHealth Group operates as a diversified healthcare company with three primary segments: UnitedHealthcare, which provides health insurance coverage; Optum Health, which delivers healthcare services and technology; and OptumRx, which manages pharmacy benefits. The company serves millions of individuals and employers across the United States, positioning itself as a critical player in the US healthcare system. UnitedHealth's integrated model allows it to manage both the insurance and care delivery sides of healthcare, creating operational synergies and multiple revenue streams.

First-quarter performance and analyst outlook

The first-quarter earnings beat reflects strong operational performance across UnitedHealth's business segments. The $7.23 EPS result exceeded analyst expectations by $0.47 per share, while revenue growth of $1.81 billion above consensus suggests robust demand for the company's insurance and healthcare services offerings. JPMorgan's price target increase to $420 implies potential upside from the May 8 closing price of $379.49, representing approximately 10.6% appreciation potential. The Overweight rating underscores analyst confidence in the company's ability to navigate a complex healthcare environment while maintaining profitability.

Conclusion

UnitedHealth Group's first-quarter earnings beat and JPMorgan's price target increase signal positive momentum for the healthcare conglomerate. The company's ability to exceed both earnings and revenue expectations demonstrates operational strength in a competitive healthcare market. With 29 analysts covering the stock and a consensus rating of Moderate Buy, UnitedHealth remains a closely watched name among institutional and retail investors seeking exposure to the US healthcare sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.